Past, present and future of alteplase for acute ischemic stroke

References

• The Atlas of Heart Disease and Stroke. MacKay J, Mensah G (Eds). World Health Organisation, Geneva, Switzerland (2004).
   Google Scholar
• Martin J, Meltzer H, Elliot D. The Prevalence of Disability among Adults. Office of Population Censuses and Surveys. HMSO, London, UK (1998).
   Google Scholar
• Brainin M, Teuschl Y, Kalra L. Acute treatment and long-term management of stroke in developing countries. Lancet Neurol.6, 553–561 (2007).
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Valentine WJ, Roze S et al. Overview of costs of stroke from published, incidence-based studies spanning 16 industrialised countries. Curr. Med. Res. Opin.21, 19–27 (2005).
   PubMed Web of Science ®Google Scholar
• Vila EM, Irimia P. The cost of stroke. Cerebrovasc Dis.17(Suppl. 1), 124–129 (2004).
   PubMed Web of Science ®Google Scholar
• Dawson J, Walters MR, Lees KR. Stroke a 21st century medical emergency. Scott. Med. J.51, 34–41 (2006).
   PubMedGoogle Scholar
• Stroke: A Practical Guide to Management (2nd Edition) Warlow CP, Dennis MS, van Gijn J et al. (Eds). Blackwell Science Limited, London, UK (2001).
   Google Scholar
• Touzani O, Roussel S, MacKenzie ET. The ischaemic penumbra. Curr. Opin. Neurol.14, 83–88 (2001).
   PubMed Web of Science ®Google Scholar
• Saver J. Time is brain-quantified. Stroke37, 263–266 (2006).
   PubMed Web of Science ®Google Scholar
• Tanswell P, Seigfried E, Stang E, Krause J. Pharmacokinetics and hepatic catabolism of tissue type plasminogen activator. Arzneimittelforschung41, 1310–1319 (1991).
   PubMed Web of Science ®Google Scholar
• Blasi F, Riccio A, Sebastio G. Human plasminogen activators. Genes and proteins structure. Horiz. Biochem. Biophysics.8, 377–416 (1986).
   PubMedGoogle Scholar
• Tanswell P, Tebbe U, Neuhaus KL, Glasle-Schwarz L, Wojcik J, Seifried E. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J. Am. Coll. Cardiol.19, 1071–1075 (1992).
   PubMed Web of Science ®Google Scholar
• Collen D, Lijnen HR. Tissue-type plasminogen activator. Mechanisms of action and thrombolytic properties. Haemostasis16(Suppl. 3), 25–32 (1986).
   PubMedGoogle Scholar
• Otter M, Kuiper J, van Berkel TJ, Rijken DC. Mechanisms of tissue type plasminogen activator clearance by the liver. Ann. NY Acad. Sci.667, 431–442 (1992).
   PubMed Web of Science ®Google Scholar
• Hill MD, Ly T, Moss H et al. Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology60, 1525–1527 (2003).
   PubMed Web of Science ®Google Scholar
• Engelter ST, Fluri F, Buitrago-Tellez C et al. Life-threatening orolingual angioedema during thrombolysis in acute ischemic stroke. J. Neurol.252, 1167–1170 (2005).
   PubMed Web of Science ®Google Scholar
• Hill MD, Buchan AM. Canadian Alteplase for Stroke Effectiveness Study (CASES) investigators. Thrombolysis for acute ischemic stroke: results of the Canadian alteplase for stroke effectiveness study. Can. Med. Assoc. J.172, 1307–1312 (2005).
   PubMed Web of Science ®Google Scholar
• Fibrinolytic Therapy Trialists. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet343, 311–322 (1994).
   PubMed Web of Science ®Google Scholar
• Donnan GA, Davis SM, Chambers BR et al. Streptokinase for acute ischaemic stroke with relationship to time administration. JAMA276, 961–966 (1996).
   PubMed Web of Science ®Google Scholar
• Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet356, 1509–1514 (1996).
   Google Scholar
• Multicenter Acute Stroke Trial – Europe Study Group. Thrombolytic therapy with streptokinase in acute ischaemic stroke. N. Engl. J. Med.335, 145–150 (1996).
   PubMed Web of Science ®Google Scholar
• Ziven JA, Fisher M, Degirolami U, Hemenway CC, Stashak JA. Tissue plasminogen activator. Reduction of neurological damage after experimental embolic stroke. Arch. Neurol.45, 387–391 (1988).
   PubMedGoogle Scholar
• Ziven JA, Fisher M, Degirolami U, Hemenway CC, Stashak JA. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science230, 1289–1292 (1985).
   PubMed Web of Science ®Google Scholar
• del Zoppo GJ. Investigational use of tPA in acute stroke. Ann. Emerg. Med.17, 1196–1201 (1988).
   PubMed Web of Science ®Google Scholar
• Brott TG, Haley EC, Levy DE et al. Urgent therapy for stroke part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke23, 632–640 (1992).
   PubMed Web of Science ®Google Scholar
• Haley EC, Brott TG, Sheppard GL et al. Urgent therapy for stroke part II. Pilot study of tissue plasminogen activator administered within 91–180 minutes from onset. Stroke23, 641–645 (1992).
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Fieschi C et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) JAMA274, 1017–1025 (1995).
   PubMed Web of Science ®Google Scholar
• Fisher M, Pessin MS, Furian AJ. ECASS: lessons for future thrombolytic stroke trials. European Cooperative Acute Stroke Study. JAMA274, 1058–1059 (1994).
   Web of Science ®Google Scholar
• Hacke W, Kaste M, Fieschi C et al. Randomised double blind placebo controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) Second European-Australasian Acute Stroke Study Investigators. Lancet352, 1245–1251 (1998).
   PubMed Web of Science ®Google Scholar
• van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, Gijn JV. Interobserver agreement for the assessment of handicap in stroke patients. Stroke19, 604–607 (1988)
   PubMed Web of Science ®Google Scholar
• The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischaemic stroke N. Engl. J. Med.333, 1581–1587 (1995).
   PubMed Web of Science ®Google Scholar
• Kwiatkowski TG, Libmann RB, Frankel M et al Effects of tissue plasminogen activator for acute ischaemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N. Engl. J. Med.340, 1781–1787 (1999).
   PubMed Web of Science ®Google Scholar
• Ardern-holmes SL, Raman R, Anderson NE, Charleston AJ, Bennett P. Opinion of New Zealand physicians on management of acute ischaemic stroke: results of a national survey. Aust. NZ J. Med.29, 324–330 (1999).
   PubMedGoogle Scholar
• Lenzer J. Alteplase for stroke: money and optimistic claims buttress the “brain attack” campaign. Brit. Med. J.324, 723–729 (2002).
   PubMedGoogle Scholar
• Wardlaw JM, Lindely RI, Lewis S. Thrombolysis for acute ischemic stroke: still a treatment for the few by the few. West J. Med.176, 198–199 (2002).
   PubMedGoogle Scholar
• Ingall TJ, O’Fallon WM, Asplund K et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke35, 2418–2424 (2004).
   PubMed Web of Science ®Google Scholar
• Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0–6 hour acute stroke trial, part a (A0276g): results of a double blind placebo-controlled, multi-centre study. Thrombolytic therapy in acute ischaemic stroke study investigators. Stroke31, 811–816 (2000).
   PubMed Web of Science ®Google Scholar
• Clark WM, Wissman S, Albers GW, Jhamandas JH, Maden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischaemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomised controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischaemic stroke JAMA282, 2019–2026 (1999).
   PubMed Web of Science ®Google Scholar
• Young FB, Lees KR, Weir CJ; for the GAIN International Trial Steering Committee and Investigators. Improving trial power through use of prognosis-adjusted end points. Stroke36, 597–601 (2005).
   PubMed Web of Science ®Google Scholar
• ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral asprin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet2, 349–360 (1988).
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin. Trials7, 177–188 (1986).
   PubMedGoogle Scholar
• Hacke W, Donnan G, Fieschi C et al. ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS and NINDS rt-PA stroke trials. Lancet363, 768–774 (2004).
   PubMed Web of Science ®Google Scholar
• Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch. Neurol.61, 1066–1070 (2004).
   PubMed Web of Science ®Google Scholar
• Demaerschalk BM. Thrombolytic therapy for acute ischaemic stroke: the likelihood of being helped versus harmed. Stroke38, 2215–2216 (2007).
   PubMed Web of Science ®Google Scholar
• Wardlaw JM, del Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst. Rev.3, CD000213 (2003).
   Google Scholar
• Wardlaw JM, Sandercock PAG, Berge E. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischaemic stroke. Where do we go from here? A cumulative meta-analysis. Stroke34, 1437–1442 (2003).
   PubMed Web of Science ®Google Scholar
• Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA283, 1145–1150 (2000).
   PubMed Web of Science ®Google Scholar
• Schmulling S, Grond M, Rudolf J, Heiss W. One year follow up in acute stroke patients treated with rt-PA in clinical routine Stroke31, 1552–1554 (2000).
   PubMed Web of Science ®Google Scholar
• Wahlgren N, Ahmed N, Davalos A et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet369, 275–282 (2007).
   PubMed Web of Science ®Google Scholar
• Nor AM, Davis J, Sen B et al. The Recognition of Stroke in the Emergency Room (ROSIER) scale: development and validation of a stroke recognition instrument. Lancet Neurol.4, 727–734 (2005).
   PubMed Web of Science ®Google Scholar
• Hess DC, Wang S, Gross H, Nichols FT, Hall CE, Adams RJ. Telestroke: extending stroke expertise into underserved areas. Lancet Neurol.5, 275–278 (2006).
   PubMed Web of Science ®Google Scholar
• Brown DL, Barsan WG, Lisabeth LD, Gallery ME, Morgenstern LB. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischaemic stroke. Ann. Emerg. Med.46, 56–60 (2005).
   PubMed Web of Science ®Google Scholar
• Sandercock P, Berge E, Dennis M et al. A systematic review of the effectiveness, cost–effectiveness and barriers to implementation of thrombolytic and neuroprotectant therapy for acute ischaemic stroke in the NHS. Health Technol. Assess.6, 1–102 (2002).
   PubMedGoogle Scholar
• Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the United Kingdom. Pharmacoeconomics21, 43–50 (2003).
   PubMed Web of Science ®Google Scholar
• Fagan S, Morgenstein S, Petitta S et al. Cost effectiveness of tissue plasminogen activator for acute ischaemic stroke. Neurology50, 833–890 (1988).
   Google Scholar
• Sinclair S, Frighetto L, Loewen P et al. Cost utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke. A Canadian health care perspective. Pharmacoeconomics19, 927–936 (2001).
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical excellence. Alteplase for the Treatment of Acute Ischaemic Stroke. MidCity Place, London, UK (2007).
   Google Scholar
• Yip TR, Demaerschalk BM. Estimated cost savings of increased use of intravenous tissue plasminogen activator for acute ischaemic stroke in Canada. Stroke38, 1952–1955 (2007).
   PubMed Web of Science ®Google Scholar
• Demaerschalk BM, Yip TR. Economic benefit of increasing utilisation of intravenous tissue plasminogen activator for acute ischaemic stroke in the United States. Stroke36, 2500–2503 (2005).
   PubMed Web of Science ®Google Scholar
• Tanne D, Kasner SE, Demchuck Am et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischaemic stroke in clinical practice: the multi-centre r-tPA stroke survey. Circulation105, 9094–9095 (2002).
   Google Scholar
• Elkind MS. Stroke in the elderly. Mt Sinai J. Med.70, 27–37 (2003).
   PubMed Web of Science ®Google Scholar
• Engelter ST, Bonati LH, Lyrer PA. Intravenous thrombolysis in stroke patients of > or = 80 versus < 80 years of age – a systematic review across cohort studies. Age Ageing35, 572–580 (2006).
   PubMed Web of Science ®Google Scholar
• Chen CI, Iguchi Y, Grotta JC et al. Intravenous t-PA for very old stroke patients. Eur. Neurol.54, 140–144 (2005).
   PubMed Web of Science ®Google Scholar
• Sylaja PN, Cote R, Buchan AM, Hill MD. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study J. Neurol. Neurosurg. Psychiatr.77, 826–829 (2006).
   PubMed Web of Science ®Google Scholar
• Van Oostenbrugge RJ, Hupperts RM, Lodder J. Thrombolysis for acute stroke with special emphasis on the very old: experience from a single Dutch centre J. Neurol. Neurosurg. Psychiatr.77, 375–377 (2006).
   PubMed Web of Science ®Google Scholar
• Dirks M, Niessen LW, Koudstaal PJ, Franke CL, van Oostenbrugge RJ, Dippel DWJ. Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contraindications. An International Delphi Study. J. Neurol. Neurosurg. Psychiatr.78, 685–689 (2007).
   PubMed Web of Science ®Google Scholar
• Quinn TJ, Reid JLR. Hypertension in acute stroke in European Society of Hypertension – Manual of Hypertension. Mancia G (Ed.) Taylor and Francis, UK, 341–352 (2007).
   Google Scholar
• Castillo J, Kleira R, Garcia MM, Serena J, Blanco M, Davalos A. Blood pressure decrease during the acute phase of stroke is associated with brain injury and poor stroke outcome. Stroke35, 520–526 (2004).
   PubMed Web of Science ®Google Scholar
• Armario P, Ceresuela LM, Bello J et al. The role of blood pressure in the prognosis of acute ischaemic stroke. J. Hypertens.19(Suppl. 2), S13 (2001).
   PubMed Web of Science ®Google Scholar
• Larrue V, von Kummer R, Muller A et al. Risk factors for severe hemorrhagic transformation in ischaemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European Australian Acute Stroke Study ECASS II Stroke32, 438–441 (2001).
   PubMed Web of Science ®Google Scholar
• Adams HP Jr, del Zoppo G, Alberts MJ et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Stroke38, 1655–1711 (2007).
   PubMed Web of Science ®Google Scholar
• Brott T, Lu M, Kothari R et al. Hypertension and its treatment in the NINDS rt-PA stroke trial. Stroke29, 1504–1509 (1998).
   PubMed Web of Science ®Google Scholar
• Katzan Il, Sila CA, Furlan AJ. Community use of intravenous tissue plasminogen activator for acute stroke: results of the brain matters stroke management survey Stroke32, 861–865 (2001).
   PubMed Web of Science ®Google Scholar
• Smith EE, Abdulah AR, Petkovska I et al. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischaemic stroke. Stroke36, 2497–2499 (2005).
   PubMed Web of Science ®Google Scholar
• Gonzales N, Albright K, Noser E et al. ‘Mild stroke’ should not exclude patients from thrombolytic therapy. Stroke37, 621 (2006).
   Google Scholar
• Baumann CR, Baumgartner RW, Gandjour J, von Budingden HC, Siegel AM, Georgiadis D. Good outcomes in ischaemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptoms. Stroke37, 1332–1333 (2006).
   PubMed Web of Science ®Google Scholar
• The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischaemic stroke. Stroke28, 2109–2118 (1997).
   PubMed Web of Science ®Google Scholar
• Saver JL. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke38, 2279–2283 (2007).
   PubMed Web of Science ®Google Scholar
• Davis SM, Donnan GA, Butcher KS, Parsons M. Selection of thrombolytic therapy beyond 3 h using magnetic resonance imaging. Curr. Opin. Neurol.18, 47–52 (2005).
   PubMed Web of Science ®Google Scholar
• Furlan AJ, Eyding D, Albers GW et al. DEDAS Investigators. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke37, 1227–1231 (2006).
   PubMed Web of Science ®Google Scholar
• Hacke W, Albers G, Al-Rawi Y et al. DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a Phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke36, 66–73 (2005).
   PubMed Web of Science ®Google Scholar
• Hacke W, Furlan A; for the DIAS-2 investigators. Results from the Phase III study of desmoteplase in acute ischaemic stroke trial (DIAS 2). Cerebrovasc. Dis.23(Suppl. 2), 54 (2007).
   Google Scholar
• Trouillas P, Hermier M, Nighoghossian N, Cakmak S, Mahagne MH, Derex L. Results of the fralyse MRI randomised study: effect of the duration of rt-PA infusion on the recanalization rate and post-pre thrombolytic changes of DWI-PWI parameters. Cerebrovasc. Dis.23(Suppl. 2) 54 (2007).
   Google Scholar
• Keyt BA, Paoni NF, Refino CJ et al. A faster-acting and more potent form of tissue plasminogen activator. Proc. Natl Acad. Sci. USA91, 3670–3674 (1994).
   PubMed Web of Science ®Google Scholar
• Haley EC, Lyden PD, Johnston KC, Hemmen TM. TNK in Stroke Investigators. A pilot dose escalation study safety study of tenecteplase in acute ischaemic stroke. Stroke36, 607–612 (2005).
   PubMed Web of Science ®Google Scholar
• Hennerici MG, Kay R, Bogousslavsky J et al. Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial. Lancet368, 1871–1878 (2006).
   PubMed Web of Science ®Google Scholar
• Lewandowski CA, Frankel M, Tomsick TA et al. Combined intravenous and intra-arterial rt-PA versus intra-arterial therapy of acute ischaemic stroke: emergency management of stroke bridging trial. Stroke30, 2598–2605 (1999).
   PubMed Web of Science ®Google Scholar
• Arnold M, Nedeltchev K, Schroth G et al. Clinical and radiological predictors of recanalisation and outome of 40 patients with acute basilar artery occlusion treated with intraarterial thrombolysis. J. Neurol. Neurosurg. Psych.75, 857–862 (2004).
   PubMed Web of Science ®Google Scholar
• Furlan A, Higashida R, Wechsler L et al. Intra-arterial thrombolysis for acute ischaemic stroke. The PROACT II study: a randomised controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA282, 2003–2011 (1999).
   PubMed Web of Science ®Google Scholar
• Alexandrov AV, Molina CA, Grotta JC et al. CLOTBUST Investigators. Ultrasound enhanced systematic thrombolysis for acute ischaemic stroke N. Engl. J. Med.351, 2170–2178 (2004).
   PubMed Web of Science ®Google Scholar
• Flint AC, Duckwiler GR, Budzik RF, Liebeskind DS, Smith WS. MERCI and Multi MERCI Writing Committee. Mechanical thrombectomy of intracranial internal carotid occlusion: pooled results of the MERCI and Multi MERCI Part I trials. Stroke38, 1274–1280 (2007).
   PubMed Web of Science ®Google Scholar
• Quinn TJ, Lees KR. Advances in emerging therapies 2007. Stroke39, 255–257 (2008).
   PubMed Web of Science ®Google Scholar
• Hanley D for the CLEAR IVH Investigative team Results of CLEAR IVH: Dose Response for 3rd and 4th ventricular blood clearance. Cerebrovasc. Dis.23, 54 (2007).
   Google Scholar
• Lees KR. Stroke is best managed by a neurologist: battle of the titans. Stroke34, 2764–2765 (2003).
   PubMed Web of Science ®Google Scholar
• Audebert H, Telestroke: effective networking Lancet Neurol.5, 279–282 (2006).
   PubMed Web of Science ®Google Scholar